Please wait while the formulary information is being retrieved.
Drug overview for NASAL SPRAY (oxymetazoline hcl):
Generic name: OXYMETAZOLINE HCL
Drug class: Amphetamines/Anorexiants/Stimulants
Therapeutic class: Respiratory Therapy Agents
Oxymetazoline hydrochloride, an imidazoline-derivative sympathomimetic Phenylephrine hydrochloride, synthetic sympathomimetic amine, is a amine, is a vasoconstrictor. vasoconstrictor.
No enhanced Uses information available for this drug.
Generic name: OXYMETAZOLINE HCL
Drug class: Amphetamines/Anorexiants/Stimulants
Therapeutic class: Respiratory Therapy Agents
Oxymetazoline hydrochloride, an imidazoline-derivative sympathomimetic Phenylephrine hydrochloride, synthetic sympathomimetic amine, is a amine, is a vasoconstrictor. vasoconstrictor.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for NASAL SPRAY (oxymetazoline hcl) have been approved by the FDA:
Indications:
Eustachian tube congestion
Nasal congestion
Rhinorrhea
Professional Synonyms:
Eustachian tube hyperemia
Nasal stuffiness
Indications:
Eustachian tube congestion
Nasal congestion
Rhinorrhea
Professional Synonyms:
Eustachian tube hyperemia
Nasal stuffiness
The following dosing information is available for NASAL SPRAY (oxymetazoline hcl):
To produce decongestion of the conjunctiva, 1 or 2 drops of a 0.12-0.25% ophthalmic solution of phenylephrine hydrochloride may be applied topically to the conjunctiva every 3-4 hours (up to 4 times daily for self-medication) as needed.
Vasoconstriction for diagnosis of ocular congestion or to improve visualization of ocular blood vessels in sickle-cell disease may be achieved by application of 1 or 2 drops of a 2.5% solution. In the ''blanching test'', congestion probably is caused by conjunctivitis rather than iridocyclitis if the drug produces perilimbal blanching in the congested eye.
A 2.5 or 10% solution of the drug may also be administered prior to surgery to produce mydriasis and aid in controlling hemorrhage. (See Phenylephrine Hydrochloride 52:24.)
To produce nasal decongestion in adults and children 12 years of age or older, the usual dosage is 2 or 3 drops, 1-3 sprays, or 1-3 metered sprays instilled in each nostril. In cases of extreme nasal congestion in adults, a 1% solution may be used initially. To produce nasal decongestion in children 6-12 years of age, 2 or 3 drops or 1 or 2 sprays of a 0.25%
solution may be instilled in each nostril. Doses of the drug as drops or spray may be repeated in 4 hours if needed. Phenylephrine nasal solutions should not be used for self-medication for longer than 3 days; if symptoms persist, the drug should be discontinued and a physician consulted.
Intranasal application of phenylephrine should generally be used for no longer than 3-5 days.
For use with local anesthetics, phenylephrine hydrochloride may be used in concentrations of 1:2500 to 1:20,000.
Vasoconstriction for diagnosis of ocular congestion or to improve visualization of ocular blood vessels in sickle-cell disease may be achieved by application of 1 or 2 drops of a 2.5% solution. In the ''blanching test'', congestion probably is caused by conjunctivitis rather than iridocyclitis if the drug produces perilimbal blanching in the congested eye.
A 2.5 or 10% solution of the drug may also be administered prior to surgery to produce mydriasis and aid in controlling hemorrhage. (See Phenylephrine Hydrochloride 52:24.)
To produce nasal decongestion in adults and children 12 years of age or older, the usual dosage is 2 or 3 drops, 1-3 sprays, or 1-3 metered sprays instilled in each nostril. In cases of extreme nasal congestion in adults, a 1% solution may be used initially. To produce nasal decongestion in children 6-12 years of age, 2 or 3 drops or 1 or 2 sprays of a 0.25%
solution may be instilled in each nostril. Doses of the drug as drops or spray may be repeated in 4 hours if needed. Phenylephrine nasal solutions should not be used for self-medication for longer than 3 days; if symptoms persist, the drug should be discontinued and a physician consulted.
Intranasal application of phenylephrine should generally be used for no longer than 3-5 days.
For use with local anesthetics, phenylephrine hydrochloride may be used in concentrations of 1:2500 to 1:20,000.
Oxymetazoline hydrochloride nasal solutions are applied topically to the Phenylephrine hydrochloride ophthalmic solutions are applied topically to nasal mucosa as sprays. Oxymetazoline hydrochloride nasal solutions also the conjunctiva. Digital pressure should be applied on the lacrimal sac for 1-2 minutes following topical instillation of ophthalmic solutions to are administered by a nasal pump that produces metered sprays.
Ophthalmic minimize drainage into the nose and throat and reduce the risk of solutions of the drug are applied topically to the conjunctiva. Care must absorption and systemic reactions. Excess solution around the eye should be be taken to avoid contamination of the dropper, inhaler, or spray dispenser.
It is recommended that contact lenses be removed before topical removed with a tissue. administration of the ophthalmic solution. For intranasal applications, phenylephrine may be administered in solution as drops or spray.
Vicks Sinex(R) (with mist spray nozzle) nasal solution Sprays (including metered sprays) should be delivered or pumped into each is administered by nasal inhalation using a special nasal inhaler that nostril with the patient's head erect so that excess solution is not produces metered droplet sprays. Care must be taken to avoid contamination released. Prior to initial use of metered sprays, the nasal inhalers should be primed by depressing the pump firmly several times.
To minimize the risk of the dropper, inhaler, or spray. Except in young children in whom sprays are difficult to use, nasal sprays may be preferable to drops because of of spreading infections, droppers, inhalers, and spray dispensers should not be used by more than one person, and tips of the dispensers, inhalers, the lesser risk of swallowing the drug and resultant systemic absorption. Drops should be applied to the dependent (lower) nostril, with the patient or droppers should be rinsed with hot water or wiped clean following use.
in a lateral head-low position. The patient should remain in the same position for 5 minutes, then the solution should be applied to the other nostril in a similar manner. Alternatively, drops may be instilled when the patient is reclining with the head tilted back as far as possible.
Sprays should be delivered or pumped (Vicks Sinex(R) metered spray) into each nostril with the patient's head erect so that excess solution is not released. The nose should be blown thoroughly 3-5 minutes later. Prior to initial use of the metered sprays, the nasal inhaler must be primed by depressing the pump firmly several times.
To minimize the risk of spreading infections, droppers, inhalers, and spray dispensers should not be used by more than one person, and tips of the dispensers, inhalers, or droppers should be rinsed with hot water following use. Phenylephrine nasal solutions also may be applied to a tampon or nasal pack for insertion into nasal passages. However, this method of application should be restricted to use in diagnostic or surgical procedures performed under medical supervision because mechanical injury may occur.
Ophthalmic minimize drainage into the nose and throat and reduce the risk of solutions of the drug are applied topically to the conjunctiva. Care must absorption and systemic reactions. Excess solution around the eye should be be taken to avoid contamination of the dropper, inhaler, or spray dispenser.
It is recommended that contact lenses be removed before topical removed with a tissue. administration of the ophthalmic solution. For intranasal applications, phenylephrine may be administered in solution as drops or spray.
Vicks Sinex(R) (with mist spray nozzle) nasal solution Sprays (including metered sprays) should be delivered or pumped into each is administered by nasal inhalation using a special nasal inhaler that nostril with the patient's head erect so that excess solution is not produces metered droplet sprays. Care must be taken to avoid contamination released. Prior to initial use of metered sprays, the nasal inhalers should be primed by depressing the pump firmly several times.
To minimize the risk of the dropper, inhaler, or spray. Except in young children in whom sprays are difficult to use, nasal sprays may be preferable to drops because of of spreading infections, droppers, inhalers, and spray dispensers should not be used by more than one person, and tips of the dispensers, inhalers, the lesser risk of swallowing the drug and resultant systemic absorption. Drops should be applied to the dependent (lower) nostril, with the patient or droppers should be rinsed with hot water or wiped clean following use.
in a lateral head-low position. The patient should remain in the same position for 5 minutes, then the solution should be applied to the other nostril in a similar manner. Alternatively, drops may be instilled when the patient is reclining with the head tilted back as far as possible.
Sprays should be delivered or pumped (Vicks Sinex(R) metered spray) into each nostril with the patient's head erect so that excess solution is not released. The nose should be blown thoroughly 3-5 minutes later. Prior to initial use of the metered sprays, the nasal inhaler must be primed by depressing the pump firmly several times.
To minimize the risk of spreading infections, droppers, inhalers, and spray dispensers should not be used by more than one person, and tips of the dispensers, inhalers, or droppers should be rinsed with hot water following use. Phenylephrine nasal solutions also may be applied to a tampon or nasal pack for insertion into nasal passages. However, this method of application should be restricted to use in diagnostic or surgical procedures performed under medical supervision because mechanical injury may occur.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for NASAL SPRAY (oxymetazoline hcl):
There are 0 contraindications.
There are 0 severe interactions.
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Zavegepant/Intranasal Decongestants SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Intranasal decongestants may decrease the absorption of zavegepant.(1) CLINICAL EFFECTS: Concurrent administration of intranasal decongestants may result in decreased systemic exposure and effectiveness of zavegepant.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Avoid concurrent use of intranasal decongestants with zavegepant. If concurrent use is unavoidable, use the decongestant at least 1 hour after zavegepant.(1) DISCUSSION: Intranasal decongestants may lower absorption of zavegepant. This effect has not been clinically evaluated.(1) |
ZAVZPRET |
The following contraindication information is available for NASAL SPRAY (oxymetazoline hcl):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 2 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Angle-closure glaucoma |
| Benign prostatic hyperplasia |
There are 5 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Atherosclerotic cardiovascular disease |
| Coronary artery disease |
| Diabetes mellitus |
| Hypertension |
| Hyperthyroidism |
The following adverse reaction information is available for NASAL SPRAY (oxymetazoline hcl):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 16 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Dizziness Headache disorder Insomnia Nervousness Rebound nasal congestion Tremor |
| Rare/Very Rare |
|---|
|
Cardiac arrhythmia Dizziness Headache disorder Hyperhidrosis Hypertension Insomnia Nervousness Pallor Tachycardia Tremor |
There are 6 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Dry nose Nasal passage irritation Rhinorrhea Sneezing |
| Rare/Very Rare |
|---|
|
Nausea Palpitations |
The following precautions are available for NASAL SPRAY (oxymetazoline hcl):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Safe use of oxymetazoline during pregnancy has not been established. Oxymetazoline hydrochloride ophthalmic or nasal solutions should be used during pregnancy only when instructed by a clinician. Animal reproduction studies have not been performed with phenylephrine.
It is not known whether topically applied phenylephrine can cause fetal harm when administered to pregnant women. Parenterally administered phenylephrine in late pregnancy or labor may cause fetal anoxia. (See Cautions: Pregnancy and Lactation, in Phenylephrine Hydrochloride 12:12.04.) Topically applied phenylephrine should be used during pregnancy only when clearly needed.
It is not known whether topically applied phenylephrine can cause fetal harm when administered to pregnant women. Parenterally administered phenylephrine in late pregnancy or labor may cause fetal anoxia. (See Cautions: Pregnancy and Lactation, in Phenylephrine Hydrochloride 12:12.04.) Topically applied phenylephrine should be used during pregnancy only when clearly needed.
It is not known whether oxymetazoline is distributed into milk. Topical oxymetazoline preparations should be used with caution in nursing women. Since it is not known whether phenylephrine is distributed into milk, the drug should be used with caution in nursing women.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for NASAL SPRAY (oxymetazoline hcl):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for NASAL SPRAY (oxymetazoline hcl)'s list of indications:
| Eustachian tube congestion | |
| H69.80 | Other specified disorders of eustachian tube, unspecified ear |
| H69.81 | Other specified disorders of eustachian tube, right ear |
| H69.82 | Other specified disorders of eustachian tube, left ear |
| H69.83 | Other specified disorders of eustachian tube, bilateral |
| Nasal congestion | |
| R09.81 | Nasal congestion |
| Rhinorrhea | |
| R09.82 | Postnasal drip |
Formulary Reference Tool